← Back to Search

Topical Ointment

Part A, Active dose A and Low body surface area for Psoriasis

Phase 1
Waitlist Available
Research Sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 to day 22

Summary

This trial is testing a special skin cream called YR001 on healthy adults to see if it is safe, well-tolerated, and how it behaves in the body.

Eligible Conditions
  • Psoriasis
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 to day 22
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 to day 22 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part A: Safety and Maximum Tolerate Dose (MTD)
Part B: Safety and Maximum Tolerate Dose (MTD)
Secondary study objectives
Part A: all treatment-emergent AEs
Part B: all treatment-emergent AEs

Trial Design

12Treatment groups
Experimental Treatment
Placebo Group
Group I: Part B, Active dose B and High body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose B on high body surface area twice daily, high dose YR001 for multiple topical administration
Group II: Part B, Active dose A and High body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose A on high body surface area twice daily, low dose YR001 for multiple topical administration
Group III: Part A, Active dose B and Middle body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose B on middle body surface area, high dose YR001 for single topical administration
Group IV: Part A, Active dose B and Low body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose B on low body surface area, high dose YR001 for single topical administration
Group V: Part A, Active dose B and High body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose B on high body surface area, high dose YR001 for single topical administration
Group VI: Part A, Active dose A and Middle body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose A on middle body surface area, low dose for single topical administration
Group VII: Part A, Active dose A and Low body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose A on low body surface area, low dose YR001 for single topical administration
Group VIII: Part A, Active dose A and High body surface areaExperimental Treatment1 Intervention
The intervention is YR001 Dose A on high body surface area, low dose for single topical administration
Group IX: Part A, Placebo and Low body surface areaPlacebo Group1 Intervention
The intervention is Placebo on low body surface area, Placebo for single topical administration
Group X: Part A, Placebo and Middle body surface areaPlacebo Group1 Intervention
The intervention is Placebo on middle body surface area, Placebo for single topical administration
Group XI: Part A, Placebo and High body surface areaPlacebo Group1 Intervention
The intervention is Placebo on high body surface area, Placebo for single topical administration
Group XII: Part B, Placebo and High body surface areaPlacebo Group1 Intervention
The intervention is Placebo on high body surface area twice daily, Placebo for multiple topical administration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
YR001 Dose A on low body surface area
2023
Completed Phase 1
~60
YR001 Dose A on middle body surface area
2023
Completed Phase 1
~60
YR001 Dose A on high body surface area
2023
Completed Phase 1
~60
YR001 Dose B on low body surface area
2023
Completed Phase 1
~60
YR001 Dose B on middle body surface area
2023
Completed Phase 1
~60
YR001 Dose B on high body surface area
2023
Completed Phase 1
~60
YR001 Dose A on high body surface area twice daily
2023
Completed Phase 1
~60
YR001 Dose B on high body surface area twice daily
2023
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Hangzhou Yirui Pharmaceutical Technology Co., LtdLead Sponsor
1 Previous Clinical Trials
36 Total Patients Enrolled
Stacy Smith, Dr. MDStudy DirectorEncinitas, California USA

Media Library

YR001 (Topical Ointment) Clinical Trial Eligibility Overview. Trial Name: NCT05718921 — Phase 1
Psoriasis Research Study Groups: Part A, Active dose A and Low body surface area, Part A, Active dose A and Middle body surface area, Part A, Active dose A and High body surface area, Part A, Active dose B and Low body surface area, Part A, Active dose B and Middle body surface area, Part A, Active dose B and High body surface area, Part A, Placebo and Low body surface area, Part A, Placebo and Middle body surface area, Part A, Placebo and High body surface area, Part B, Active dose A and High body surface area, Part B, Active dose B and High body surface area, Part B, Placebo and High body surface area
Psoriasis Clinical Trial 2023: YR001 Highlights & Side Effects. Trial Name: NCT05718921 — Phase 1
YR001 (Topical Ointment) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05718921 — Phase 1
~22 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top